Clinical Trial Details
— Status: Not yet recruiting
Administrative data
NCT number |
NCT06450418 |
Other study ID # |
AC24003 |
Secondary ID |
|
Status |
Not yet recruiting |
Phase |
|
First received |
|
Last updated |
|
Start date |
June 2024 |
Est. completion date |
June 2026 |
Study information
Verified date |
January 2024 |
Source |
University of Edinburgh |
Contact |
Christine R Weaver, MSc |
Phone |
01314659512 |
Email |
cweaver[@]ed.ac.uk |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
Many people living with neurodegenerative conditions like dementia, motor neuron disease
(MND), multiple sclerosis (MS), and Parkinson's disease (PD), suffer from speech problems.
Using common digital technologies such as smartphone apps, the investigators can record and
analyse speech in detail to provide new information for people living with these conditions,
researchers, and healthcare professionals. This study will investigate the use of these
digital speech recordings to help diagnose and monitor these conditions.
To take part, participants will have either a diagnosis of dementia, motor neuron disease,
Parkinson's disease or Multiple Sclerosis, OR they will have no diagnosis of a neurological
condition. Researchers will compare people with a diagnosis of a Neurological condition to
those without.
Description:
This project aims to create novel speech-based solutions for: 1) Early detection, 2)
Monitoring and 3) Stratification of neurodegenerative disorders including dementia, motor
neuron disease (MND), Parkinson's disease (PD), and multiple sclerosis(MS). The investigators
will develop and validate proof of concept and early-stage algorithms derived from acoustic
data, which will be scaled and tested in deeply-phenotyped population.
2.2 Objectives Primary Objectives
1. To deploy and iterate a digital platform, co-produced with people living with
neurodegenerative disorders, for acquisition of speech data from well characterised
cohorts of people living with neurodegenerative disorders (dementia, motor neuron
disease, multiple sclerosis, Parkinson's disease), and a healthy control cohort
(comprising relatives/carers and volunteers without a neurological diagnosis), linked to
our highly curated clinical registries at the Anne Rowling Regenerative Neurology
Clinic.
2. To collect a large body of acoustic speech data from well characterised cohorts of
people living with neurodegenerative disorders (dementia, MND/ALS, multiple sclerosis,
Parkinson's disease), and a healthy control cohort (comprising relatives/carers and
volunteers without a neurological diagnosis), linked to highly curated clinical
registries.
3. To apply machine learning approaches directly to acoustic and linguistic signals from
voices from people with dementia, MND, MS, Parkinson's, and healthy controls (comprising
relatives/carers and volunteers without a neurological diagnosis), and to characterise
prosodic patterns (rhythm, intonation, and fluency) without explicit reference to the
text which is spoken, providing powerful cues about the health of the speaker.
4. Compare speech based digital outcome measures to current clinical standards to
characterise and validate their clinimetric properties.
Secondary Objectives
1. Assess the feasibility and acceptability of a digital outcome measure platform in people
living with neurodegenerative conditions, for use in clinical care and research.
2. To create a repository of well characterised acoustic voice samples for open access
sharing/collaboration with research and industry partners.